Loading
A phase 1/2 trial of Tirapazamine in hepatocellular carcinoma and neuroendocrine tumours, run by Teclison Ltd., now recruiting.
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer is a phase 1/2 interventional study registered as NCT02174549 by Teclison Ltd., with 25 participants planned, started 2014-09 and due to reach its primary completion in 2028-03-31. Interventions recorded: Tirapazamine and Conventional Transarterial Embolization (TAE).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/